Non–Small Cell Lung Cancer Coverage from Every Angle

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: Reducing the Frequency of Nivolumab Dosing

Posted: Monday, March 4, 2019

Edward B. Garon, MD, of the Olive View–UCLA Medical Center, discusses the clinical implications of CheckMate 384 findings on reducing the frequency of nivolumab dosing from 480 mg every 4 weeks to 240 mg every 2 weeks in previously treated advanced non–small cell lung cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.